Boutros Soutou

Prof. Boutros Soutou

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2023 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
FMFarid Mallat
Farid Mallat
CCCéline Chaaya
Céline Chaaya
MAMaroun Aoun
Maroun Aoun
BSBoutros Soutou
Boutros Soutou
JHJosiane Helou
Josiane Helou
Background: With light-assisted hair removal becoming widely used, reports of adverse effects are increasing. Objective: To review all the reported optical incidents and cutaneous complications of laser or intense pulse light-assisted hair removal. Methods: A PubMed database systematic search was performed to identify studies reporting such adverse events before July 2022 using the Mesh terms “adverse effects” AND “hair removal” AND (“laser” OR “intense pulse light”). Results: Altogether, 358 references were identified. After excluding duplicates, unrelated articles, guidelines, and conference abstracts, then adding references from studies bibliography, 104 publications were included. Ocular incidents consisted of anterior uveitis, iritis and iris atrophy, pupillary distortion, posterior synechiae, anterior chamber pigment, and cataracts in the anterior subcapsular region. Cutaneous complications consisted of pain, burns, folliculitis, leukotrichia, paradoxical hypertrichosis, pigmentary changes, changes in nevi, pili bigemini, herpes infection, hyperhidrosis, bromhidrosis, Fox-Fordyce disease, and frostbite from the cooling system. They were mostly correlated to skin type and body area as well as to light device and set parameters. Intense pulse light devices were found to be less painful than alexandrite laser, yet more painful than diode laser; Nd:YAG laser had the highest pain score. Conclusion: Optical incidents can be systematically avoided. Cutaneous complications are usually related to professional errors and patient characteristics. Better knowledge of laser physics and adequate training of laser operators are key recommendations to avoid undesirable side effects. Safety recommendations help prevent most of the reported complications.

8 July 2020 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
JHJosiane Helou
Josiane Helou
JKJoelle Korkomaz
Joelle Korkomaz
FSFarid Stephan
Farid Stephan
BSBoutros Soutou
Boutros Soutou

6 March 2020 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
BSBoutros Soutou
Boutros Soutou
PSPatricia Senet
Patricia Senet
FLFrançois Lionnet
François Lionnet
AHAnoosha Habibi
Anoosha Habibi
SASélim Aractingi
Sélim Aractingi
Background: While skin carcinomas are reported in chronic ulcers and in patients treated with hydroxyurea (HU) for myeloproliferative neoplasms, no skin carcinoma has been reported in patients with sickle cell disease (SCD), presenting chronic skin ulcers or treated with HU. The objective was to estimate the risk of cutaneous malignant transformation in SCD patients with prolonged leg ulcers or under HU therapy. Results: In this cross-sectional study, the cohort consisted of 1543 patients. In the first series, 29 patients presented a total of 53 ulcers lasting more than two years. The median age was 35 ± 8.4 years old. The median duration for a single ulcer was 9.2 ± 7 years. None of the examined ulcers showed any suspicious area of malignant transformation. In the second series, 187 patients treated with HU for more than two years were identified. The median age was 31.3 ± 9.9 years old. The median duration of treatment with HU was 6 ± 3.2 years. No skin carcinoma or actinic keratosis was recorded. Conclusions: This study showed that skin carcinogenesis did not occur in our series of SCD patients exposed to transforming events such as long term HU treatment or prolonged leg ulcers.

21 January 2022 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
BSBoutros Soutou
Boutros Soutou
CMCarine Massih
Carine Massih
GSGhassan Sleilaty
Ghassan Sleilaty
VTViviane Trak-Smayra
Viviane Trak-Smayra
MNMarwan Nasr
Marwan Nasr
RTRoland Tomb
Roland Tomb

19 January 2023 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
BSBoutros Soutou
Boutros Soutou
JSJoelle Sleiman
Joelle Sleiman
RTRoland Tomb
Roland Tomb
EKElio Kechichian
Elio Kechichian
JHJosiane Helou
Josiane Helou

20 March 2024 in Indian Journal of Dermatology
Verified
Journal Article
Open access
BSBoutros Soutou
Boutros Soutou
SRSerena Rahme
Serena Rahme
ABAren Joe Bizdikian
Aren Joe Bizdikian
SSStéphanie Skaff
Stéphanie Skaff
JHJosiane Helou
Josiane Helou
RTRoland Tomb
Roland Tomb
Background: Telogen effluvium (TE) is the most common cause of alopecia in women. Treatment should address the etiological factors and may include adjuvant therapies. In practice, physicians may employ modified approaches and utilize various combinations of topical and oral molecules. Aims: In this real-life observational study, the aim was to evaluate the response of TE to iron supplementation. Materials and Methods: The population consisted of all patients who sought consultation for TE at our dermatology department between March 2021 and February 2022. Eligible participants were women, aged between 18 and 65, having a clinical diagnosis of TE, and intended for treatment with iron supplementation. Exclusion criteria comprised current pregnancy, chronic or active inflammatory disease, newly discovered dysthyroidism, concurrent use of hair supplements, topical minoxidil, or any other medications. The response was assessed based on the patient’s level of satisfaction, a significant indicator, given the substantial psychological impact of TE on women’s daily lives. Results: The analysis included 200 women. The average age was 32.9 ± 11.4 years. A recent history of COVID-19 or treated dysthyroidism was present in 18.5% and 8% of patients, respectively, but did not impact their response. Significantly, patients with baseline ferritin ≥50 ng/ml were mostly “very satisfied”, those with baseline ferritin <50 ng/ml were mostly “not satisfied”, and those with unknown levels were mostly “partially satisfied” with iron supplementation. A high dose of elemental iron and a prolonged duration of treatment significantly improved the patients’ level of satisfaction. Conclusion: Iron supplementation can improve the patient’s level of satisfaction in TE even if serum ferritin is not low.